Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Omeros Corporation today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.

1 Nov 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Novel insight into impact that Huntington's disease has on the brain

A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that Huntington's disease has on the brain.

19 Oct 2012

Scientists discover how protein deficiency may be linked to frontotemporal dementia

Using animal models, scientists at the Gladstone Institutes have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)-a form of early-onset dementia that is similar to Alzheimer's disease. These results lay the foundation for therapies that one day may benefit those who suffer from this and related diseases that wreak havoc on the brain.

9 Oct 2012

Lecture to discuss insights into genes and neurodegenerative diseases gleaned from baker's yeast

Insights into our genes and neurodegenerative diseases gleaned from humble baker's yeast, among other things, will be showcased by genetics experts at a free public lecture.

4 Oct 2012

Teva concludes Asset Transfer Agreement with NeuroSearch

Teva Pharmaceutical Industries Ltd announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark to purchase all rights, assets and obligations relating to Huntexil (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD).

28 Sep 2012

Blood test for monitoring Huntington’s disease may be possible in future

Measuring blood levels of mutant huntingtin protein may provide an alternative approach of determining the onset of Huntington’s disease in known carriers, researchers report.

26 Sep 2012

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

26 Sep 2012

Researchers identify 21 proteins that specifically bind to ataxin-1

Misfolded proteins can cause various neurodegenerative diseases such as spinocerebellar ataxias (SCAs) or Huntington's disease, which are characterized by a progressive loss of neurons in the brain. Researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, together with their colleagues of the Universit- Paris Diderot, Paris, France, have now identified 21 proteins that specifically bind to a protein called ataxin-1.

19 Sep 2012

New light-based technique demonstrates that toxic proteins build up gradually in blood cells

A new light-based technique for measuring levels of the toxic protein that causes Huntington's disease (HD) has been used to demonstrate that the protein builds up gradually in blood cells. Published today (17th) in the Journal of Clinical Investigation, the findings shed light on how the protein causes damage in the brain, and could be useful for monitoring the progression of HD, or testing new drugs aimed at suppressing production of the harmful protein.

18 Sep 2012

People with genetic mutation for Huntington's disease learn faster: Study

People who bear the genetic mutation for Huntington's disease learn faster than healthy people. The more pronounced the mutation was, the more quickly they learned. This is reported by researchers from the Ruhr-Universität Bochum and from Dortmund in the journal Current Biology.

15 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

6 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Study utilizes integrative approach to probe biology of bipolar disorder

The more that we understand the brain, the more complex it becomes. The same can be said about the genetics and neurobiology of psychiatric disorders. For "Mendelian" disorders, like Huntington disease, mutation of a single gene predictably produces a single clinical disorder, following relatively simple genetic principals. Compared to Mendelian disorders, understanding bipolar disorder has been extremely challenging. Its biology is not well understood and its genetics are complex.

21 Aug 2012

Latrepiridine reduces level of at least two neurodegeneration-related proteins in mice

14 Aug 2012

Latrepirdine demonstrates new potential against neurodegenerative conditions

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.

13 Aug 2012

Latrepirdine appears effective in treating Alzheimer's disease in animals

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.

31 Jul 2012

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Novel insight into impact that Huntington's disease has on the brain

Scientists discover how protein deficiency may be linked to frontotemporal dementia

Lecture to discuss insights into genes and neurodegenerative diseases gleaned from baker's yeast

Teva concludes Asset Transfer Agreement with NeuroSearch

Blood test for monitoring Huntington’s disease may be possible in future

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Researchers identify 21 proteins that specifically bind to ataxin-1

New light-based technique demonstrates that toxic proteins build up gradually in blood cells

People with genetic mutation for Huntington's disease learn faster: Study

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

New results describe development of DC cancer vaccine with enhanced immunogenic potential

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

Study utilizes integrative approach to probe biology of bipolar disorder

Latrepiridine reduces level of at least two neurodegeneration-related proteins in mice

Latrepirdine demonstrates new potential against neurodegenerative conditions

Latrepirdine appears effective in treating Alzheimer's disease in animals

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in